# Recurrence Rate of Hepatocellular Carcinoma After Treatment of Chronic Hepatits C Patients With Direct Acting Antivirals: Randomized Controlled Phase 3 Trial

> **NCT03551444** · PHASE3 · UNKNOWN · sponsor: **Ain Shams University** · enrollment: 80 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Hepatitis C, Chronic

## Interventions

- **DRUG:** Administration of DAA-based treatment

## Key facts

- **NCT ID:** NCT03551444
- **Lead sponsor:** Ain Shams University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-10-01
- **Primary completion:** 2019-04-01
- **Final completion:** 2019-10-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2018-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03551444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03551444, "Recurrence Rate of Hepatocellular Carcinoma After Treatment of Chronic Hepatits C Patients With Direct Acting Antivirals: Randomized Controlled Phase 3 Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03551444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*